CureVac N.V (CVAC) concluded trading on Thursday at a closing price of $5.60, with 22.91 million shares of worth about $128.27 million changed hands on the day. Half year performance of the stock remained positive as price took a surge of 66.17% during that period and on June 12, 2025 the price saw a gain of about 37.59%. Currently the company’s common shares owned by public are about 225.16M shares, out of which, 93.99M shares are available for trading.
Stock saw a price change of 25.56% in past 5 days and over the past one month there was a price change of 64.95%. Year-to-date (YTD), CVAC shares are showing a performance of 64.22% which increased to 22.00% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $2.37 but also hit the highest price of $5.00 during that period. The average intraday trading volume for CureVac N.V shares is 652.55K. The stock is currently trading 29.64% above its 20-day simple moving average (SMA20), while that difference is up 52.82% for SMA50 and it goes to 70.45% higher than SMA200.
CureVac N.V (NASDAQ: CVAC) currently have 225.16M outstanding shares and institutions hold larger chunk of about 3.57% of that.
The stock has a current market capitalization of $1.26B and its 3Y-monthly beta is at 2.49. PE ratio of stock for trailing 12 months is 6.21, while it has posted earnings per share of $0.90 in the same period. It has Quick Ratio of 7.65 while making debt-to-equity ratio of 0.06. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for CVAC, volatility over the week remained 17.55% while standing at 8.51% over the month.
Analysts are in expectations that CureVac N.V (CVAC) stock would likely to be making an EPS of -0.18 in the current quarter, while forecast for next quarter EPS is 0.1 and it is -0.37 for next year. For the current quarter EPS, analysts have given the company a lowest target -0.22 which is -0.15 at the higher side of the target for the same. When we compare those targets with actual EPS, we find that company posted an EPS of -0.32 in the same quarter a year ago. Stock’s fiscal year EPS is expected to drop by -164.53% while it is estimated to increase by 3.93% in next year.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Leerink Partners on April 25, 2024 offering a Market perform rating for the stock and assigned a target price range of between $12 and $4 to it. Coverage by SVB Securities stated CureVac N.V (CVAC) stock as an Outperform in their note to investors on June 08, 2023, suggesting a price target of $13 for the stock. On January 19, 2023, UBS Upgrade their recommendations, while on January 09, 2023, Jefferies Upgrade their ratings for the stock with a price target of $21. Stock get an Underperform rating from BofA Securities on January 21, 2022.
